IPP Bureau

AstraZeneca India launches solar project to achieve sustainability goals
AstraZeneca India launches solar project to achieve sustainability goals

By IPP Bureau - October 11, 2021

The company will shift 100 percent of its energy use to renewable sources for both power and heat by 2025 in order to achieve carbon neutrality

Gland Pharma receives tentative nod for Sugammadex injection
Gland Pharma receives tentative nod for Sugammadex injection

By IPP Bureau - October 09, 2021

The injection is used to reverse the effects of the muscle relaxants given to patients during surgery

Cyprium Therapeutics and Sentynl, a Zydus subsidiary announce positive data for CUTX-101, CuHis
Cyprium Therapeutics and Sentynl, a Zydus subsidiary announce positive data for CUTX-101, CuHis

By IPP Bureau - October 09, 2021

The rolling submission to the U.S. FDA will begin in the fourth quarter of this year

Roche’s Alzheimer antibody granted U.S. FDA Breakthrough Therapy Designation
Roche’s Alzheimer antibody granted U.S. FDA Breakthrough Therapy Designation

By IPP Bureau - October 09, 2021

Gantenerumab is an investigational antibody in Phase III development for early Alzheimer's disease (AD) and a comprehensive data set with an expected readout in mid-2022

Tezepelumab granted Orphan Drug Designation in the US
Tezepelumab granted Orphan Drug Designation in the US

By IPP Bureau - October 09, 2021

Tezepelumab has been granted Orphan Drug Designation (ODD) in the US by the U.S. Food and Drug Administration (FDA) for the treatment of eosinophilic esophagitis (EoE)

Govt clarifies on export ban of syringes
Govt clarifies on export ban of syringes

By IPP Bureau - October 09, 2021

Quantitative restrictions in place to meet domestic needs to cater to the vaccination programme

Alnylam partners with the Medicines Manufacturing Innovation Centre
Alnylam partners with the Medicines Manufacturing Innovation Centre

By IPP Bureau - October 09, 2021

Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies

ASU drug manufacturing licence goes online
ASU drug manufacturing licence goes online

By IPP Bureau - October 09, 2021

The applicants will only have to get their Good Manufacturing Practices certification validated every five years to retain their licence

Sanofi says positive results from flu vaccine with mRNA booster study
Sanofi says positive results from flu vaccine with mRNA booster study

By IPP Bureau - October 08, 2021

The first study to investigate the safety and immunogenicity of both vaccines when co-administered compared to each vaccine administered separately in adults aged 65 years and older

Cigna sells its life, accident and allied businesses to Chubb for US $ 5.75 billion
Cigna sells its life, accident and allied businesses to Chubb for US $ 5.75 billion

By IPP Bureau - October 08, 2021

The agreement will sharpen Cigna's focus on the growth path for its rapidly expanding global health portfolio

CDSCO approves Syntellix implants
CDSCO approves Syntellix implants

By IPP Bureau - October 08, 2021

This opens up a huge market for the company’s Magnezis implants in India

Lilac Insights launches mental health platform AtEase
Lilac Insights launches mental health platform AtEase

By IPP Bureau - October 08, 2021

The platform will provide a safe and nurturing space for women, and non-binary individuals

Thermo Fisher Scientific introduces On the Go mobile app in India
Thermo Fisher Scientific introduces On the Go mobile app in India

By IPP Bureau - October 07, 2021

The applications navigate through more than 100 workflows across biotech, pharma, healthcare, food, forensics, industrial and applied sciences industries

WHO gives its go-ahead for first-ever malaria vaccine
WHO gives its go-ahead for first-ever malaria vaccine

By IPP Bureau - October 07, 2021

It recommends using the vaccine to prevent the spread of the disease

Twin Health raises US $ 140 million in Series C funding
Twin Health raises US $ 140 million in Series C funding

By IPP Bureau - October 07, 2021

The start-up claims in clinical trials over 90 % achieved type 2 diabetes reversal and 92 % eliminated all diabetes medication within 90 days of joining the twin service

Latest Stories

Interviews

Packaging